相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
Niklas Mattsson-Carlgren et al.
NEUROLOGY (2022)
Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
Gemma Salvado et al.
BRAIN COMMUNICATIONS (2022)
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
Carol Van Hulle et al.
ALZHEIMERS & DEMENTIA (2021)
Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum
Gemma Salvado et al.
ALZHEIMERS & DEMENTIA (2021)
NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages
Ronald C. Petersen et al.
ANNALS OF NEUROLOGY (2021)
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
Andrea L. Benedet et al.
JAMA NEUROLOGY (2021)
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Ashvini Keshavan et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2021)
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status
June Kaplow et al.
ALZHEIMERS & DEMENTIA (2020)
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
Marta Mila-Aloma et al.
ALZHEIMERS & DEMENTIA (2020)
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
Michael Ewers et al.
EMBO Molecular Medicine (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid
Valeria Lifke et al.
CLINICAL BIOCHEMISTRY (2019)
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis
Silvia Paciotti et al.
CLINICA CHIMICA ACTA (2019)
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Claire Bridel et al.
JAMA NEUROLOGY (2019)
Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease
Michael Ewers et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Daniel Alcolea et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Measuring longitudinal cognition: Individual tests versus composites
Erin M. Jonaitis et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease
Marta Mila-Aloma et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
Shorena Janelidze et al.
JAMA NEUROLOGY (2017)
Results From the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study
Sarah E. Monsell et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2016)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers
Marc Suarez-Calvet et al.
EMBO MOLECULAR MEDICINE (2016)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
Henrik Zetterberg et al.
JAMA NEUROLOGY (2016)
The Preclinical Alzheimer Cognitive Composite Measuring Amyloid-Related Decline
Michael C. Donohue et al.
JAMA NEUROLOGY (2014)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Rebecca Craig-Schapiro et al.
BIOLOGICAL PSYCHIATRY (2010)
Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type
Barbara J. Snider et al.
ARCHIVES OF NEUROLOGY (2009)
CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment -: A follow-up study
G. Li et al.
NEUROLOGY (2007)
Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults
Anne M. Fagan et al.
ARCHIVES OF NEUROLOGY (2007)
分享论文
